KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Other Non-Current Assets

Last Annual Value

953.00K

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

KT

Kalaris Therapeutics Inc Competitors Analysis of Other Non-Current Assets

KLRS · NASDAQ
CompanyOther Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
953.00K
N/A-2.9%N/A 
-4.22M
N/AN/AN/A
919.00K
12.2%-23.7%N/A
1.44M
-17.3%30.4%N/A
0.00
N/AN/AN/A
6.03M
3.2%5.9%N/A
3.32M
1.2%67.8%37.3%
3.62M
-22.0%-17.9%N/A
337.00K
-58.5%-41.3%N/A
207.00K
-29.1%-20.5%N/A
2.52M
320.1%-36.8%66.9%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66